Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target

Yedda Li,Yue Xu,Bruno A. Benitez,Murtaza S. Nagree,Joshua T. Dearborn,Xuntian Jiang,Miguel A. Guzman,Josh C. Woloszynek,Alex Giaramita,Bryan K. Yip,Joseph Elsbernd,Michael C. Babcock,Melanie Lo,Stephen C. Fowler,David F. Wozniak,Carole A. Vogler,Jeffrey A. Medin,Brett E. Crawford,Mark S. Sands
DOI: https://doi.org/10.1073/pnas.1912108116
IF: 11.1
2019-09-16
Proceedings of the National Academy of Sciences
Abstract:Significance This study identifies the source of the toxic glycolipid, galactosylsphingosine (psychosine), which accumulates in the inherited demyelinating disorder, Krabbe disease. It was suggested that psychosine was produced anabolically by the addition of galactose to sphingosine. We show here instead that psychosine is derived from the catabolic deacylation of galactosylceramide by the lysososomal enzyme acid ceramidase. These findings allow us to test and confirm the ∼45-y-old “psychosine hypothesis,” which states that psychosine causes the pathological and clinical signs of Krabbe disease. Finally, these data suggest that acid ceramidase could be a substrate reduction target for treating Krabbe disease. We show that pharmacological inhibition of acid ceramidase significantly increases the life span of the twitcher mouse, an authentic murine model of Krabbe disease.
What problem does this paper attempt to address?